Abstract
As the incidence of nonmelanoma skin cancer (NMSC) increases, so does the number of modalities used to treat this condition. Surgery is the most frequent approach used to treat NMSC, and clinicians usually perform Mohs micrographic surgery, conventional excision, electrodesiccation and curettage or cryosurgery. The 'gold standard' for treatment continues to be Mohs micrographic surgery, but owing to the time and expense involved with this procedure, it is indicated only in patients with aggressive tumors or those where disfigurement or functional impairment is a risk. Although radiation therapy is effective, its use is limited because of the side effects induced; radiation therapy can be used in certain patients who are not surgical candidates. Newer noninvasive options for NMSC include topical chemotherapeutics, biological-immune-response modifiers, retinoids, and photodynamic therapy, which can be used particularly in patients with superficial tumors. Treatments should be tailored to tumor type, location, size, and histological pattern, and although surgical methods remain the most frequently used, newer noninvasive treatments can be used in select tumors and may reduce morbidity.
Key Points
-
The incidence of nonmelanoma skin cancer (NMSC) continues to increase, and it is estimated that 20% of Americans will develop this type of cancer during their lifetime
-
The 'gold standard' for treating NMSC is Mohs micrographic surgery, although other surgical modalities such as excision or curettage and electrodesiccation are often very effective, less expensive, and can be the treatment of choice in certain circumstances
-
Radiation therapy is an effective treatment option, although side effects of this method and the cost limit its usefulness to cases involving nonsurgical candidates
-
Newer immune-modulating agents such as imiquimod have proven effective for treating superficial variants of NMSC and can be used in instances when other methods would be difficult to perform or where cosmesis is important
-
Photodynamic therapy is an emerging treatment for superficial NMSC, although it should not be used for thicker tumors
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Cancer Society (online 20 November 2006) What is nonmelanoma skin cancer? [http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_people_get _nonmelanoma_skin_cancer_51.asp?sitearea=] (accessed 1 December 2006)
Housman TS et al. (2003) Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 48: 425–429
Chen J et al. (2001) Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 27: 1035–1038
Martinez JC and Otley CC (2001) The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc 76: 1253–1265
Nguyen T and Ho D (2002) Nonmelanoma skin cancer. Curr Treat Options Oncol 3: 193–203
Abide JM et al. (1984) The meaning of surgical margins. Plast Reconstr Surg 73: 492–497
Shriner DL et al. (1998) Mohs micrographic surgery. J Am Acad Dermatol 39: 79–97
Randle HW (1996) Basal cell carcinoma: identification and treatment of the high-risk patient. Dermatol Surg 22: 255–261
Thissen M et al. (1999) A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 135: 1177–1183
Smeets N et al. (2004) Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomized controlled trial. Lancet 364: 1766–1772
Essers B et al. (2006) Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 142: 187–194
Rowe DE et al. (1992) Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol 26: 976–990
Voss N and Kim-Sing C (1998) Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin 16: 313–320
Silverman MK et al. (1992) Recurrence rates of treated basal cell carcinomas—part 4: X-ray therapy. J Dermatol Surg Oncol 18: 549–554
Kuflik EG (1994) Cryosurgery updated. J Am Acad Dermatol 31: 925–944
Kuflik EG (1991) The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 24: 1002–1004
An KP and Ratner D (2001) Surgical management of cutaneous malignancies. Clin Dermatol 19: 305–320
Rowe DE et al. (1989) Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15: 315–326
Sheridan A and Dawber R (2000) Curettage, electrosurgery, and skin cancer. Australas J Dermatol 41: 19–30
Kopf AW et al. (1977) Curettage and electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 133: 439–443
Chakrabarty A and Geisse J (2004) Medical therapies for non-melanoma skin cancer. Clin Dermatol 22: 183–188
Goette DK (1981) Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 6: 633–649
Acarturk TO and Edington H (2005) Nonmelanoma skin cancer. Clin Plastic Surg 32: 237–248
Dillaha J et al. (1983) Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 119: 774–783
Mohs FE et al. (1978) Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol 114: 1021–1022
Berman B (2002) Imiquimod: a new immune response modulator for the treatment of external genital warts and other diseases in dermatology. Int J Dermatol 41 (Suppl 1): S7–S11
Meyer T et al. (2003) Induction of apoptosis by toll-like receptor 7 agonist in tissue cultures. Br J Dermatol 149 (Suppl 66): S9–S14
Sullivan TP et al. (2003) Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 29: 1181–1186
Marks R et al. (2001) Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44: 807–813
US Food and Drug Administration (online 14 July 2004) Aldara (imiquimod) 5% cream. [http://www.fda.gov/cder/foi/label/2004/20723s016lbl.pdf] (accessed 1 December 2006)
Shumack S et al. (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138: 1165–1171
Bianchi L et al. (2003) Superficial and nodular basal cell carcinoma treated with an immune response modulator: a report of seven patients. Clin Exp Dermatol 28 (Suppl 1): S24–S26
Beutner KR et al. (1999) Therapeutic response of basal cell carcinoma to the immune response modified imiquimod 5% cream. J Am Acad Dermatol 42: 1000–1007
Spencer JM (2006) Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 32: 63–69
Wu JK et al. (2006) An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 47: 46–48
Mackenzie-Wood A et al. (2001) Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 44: 462–470
Orengo I et al. (2002) Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol 47 (Suppl): S225–S228
Schroeder TL and Sengelmann RD (2002) Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 46: 545–548
Marmur ES et al. (2004) A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 30: 264–271
Sziemies R et al. (2005) Photodynamic therapy of non-melanoma skin cancer. Acta Derm Venereol 85: 483–490
Rhodes LE et al. (2004) Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma. Arch Dermatol 4: 17–23
Salim A et al. (2003) Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 148: 539–543
Morton CA et al. (2001) Photodynamic therapy for large or multiple patches of Bowen's disease and basal cell carcinoma. Arch Dermatol 137: 319–324
Niles RM (2000) Recent advances in the use of vitamin A (retinoids) in prevention and treatment of cancer. Nutrition 16: 1084–1089
Otley CC et al. (2006) Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 32: 562–568
Bavnick JN et al. (1995) Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 13: 1933–1938
DeSevaux RG et al. (2003) Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 49: 407–412
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JA Neville completed a study sponsored by 3M Pharmaceuticals and has presented this work at symposia on behalf of this company. The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Neville, J., Welch, E. & Leffell, D. Management of nonmelanoma skin cancer in 2007. Nat Rev Clin Oncol 4, 462–469 (2007). https://doi.org/10.1038/ncponc0883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0883
This article is cited by
-
Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma
Dermatology and Therapy (2023)
-
Local control comparison of early-stage non-melanoma skin Cancer (NMSC) treated by superficial radiotherapy (SRT) and external beam radiotherapy (XRT) with and without dermal image guidance: a meta-analysis
Discover Oncology (2022)
-
Loss of epidermal MCPIP1 is associated with aggressive squamous cell carcinoma
Journal of Experimental & Clinical Cancer Research (2021)
-
Lifestyle behaviors and sun exposure among individuals diagnosed with skin cancer: a cross-sectional analysis of 2018 BRFSS data
Journal of Cancer Survivorship (2021)